Due-Diligence Report · Fate Therapeutics
FT819 — Technology Validation
The first iPSC-derived, TCR-null, CD19-CAR T-cell product in the clinic. A read on whether the platform biology holds and whether the clinical thesis is supported by disclosed evidence.
Verdict
Validated platform, unvalidated clinical thesis. The engineering claims each trace to high-impact primary biology and safety is clean, but efficacy is undisclosed after 4+ years and the asset has pivoted to autoimmunity.